Current controversies in the treatment of ductal carcinoma in situ of the breast

Annali Italiani di Chirurgia

Volumn 79, Issue 3, 2008, Pages 151-156

  Franceschini, Gianluca ^a   Terribile, Daniela ^a   Magno, Stefano ^a   Fabbri, Cristina ^a   D'Alba, Pierfrancesco ^a   Chiesa, Federica ^a   Di Leone, Alba ^a   Scafetta, Ilaria ^a   Masetti, Riccardo ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Breast; Ductal carcinoma in situ; Treatment

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

BREAST TUMOR; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MASTECTOMY; METHODOLOGY; REVIEW; SEGMENTAL MASTECTOMY; TREATMENT OUTCOME;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; TAMOXIFEN; TREATMENT OUTCOME;

EID: 58149152940     PISSN: 2239253X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ashikari R, Hajdu SI, Robbins GF: Intraductal carcinoma of the breast (1960-1969). Cancer, 1971; 28:1182-187.
2. The Consensus Conference Committee: Consensus conference in the classification of ductal carcinoma in situ. Cancer, 1997; 80:1798-802.
3. Silverstein MJ, Poller DN, Waisman JR, et al: Prognostic classification of breast ductal carcinoma-in-situ. Lancet, 1995; 345:1154-157.
4. Attene F, Scognamillo F, Trignano E et al: In situ carcinomas of the breast: Clinical features and therapeutic strategies. Ann Ital Chir, 2006; 77(1):23-10; discussion 10-12.
5. Tisikitis VL, Chung MA: Biology of ductal carcinoma in situ classification based on biologic potential. Am J Clin Oncol, 2006; 29:305-10.
6. Pinder SE, Evans AJ, Ellis IO: Ductal carcinoma in situ of the human breast: Clinico-pathological aspects. Ann Ital Chir, 1999; 70(3):343-47.
7. Jo BH, Chun YK: Heterogeneity of invasive ductal carcinoma: Proposal for a hypothetical classification. J Korean Med Sci, 2006; 21:460-68.
8. Bocker W, Moll R, Poremba C, et al: Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: A new cell biological concept. Lab Invest, 2002; 82:737-45.
9. Tang P, Wang X, Schiffhauer L, et al: Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers. Ann Clin Lab Sci, 2006; 36:17-22.
10. Erbas B, Provenzano E, Armes J, Gertig D: The natural history of ductal carcinoma in situ of the breast: A review. Breast Cancer Res Treat, 2006; 97:135-44.
11. Sanders ME, Schuyler PA, Dupont WD, Page DL: The nature history of lowgrade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer, 2005; 103:2481-484.
12. Burstein HJ, Polyak K et al: Ductal Carcinoma in situ of the breast. N Engl J Med, 2004; 350:1430-441.
13. Baxter N., Beth A. et al: Trends in the treatment of ductal carcinoma in situ of the breast. Journal of the National Cancer Institute, 2004; 96-6 march 17.
14. Solin L: Is Excision Alone Adequate Treatment for Low-Risk Ductal Carcinoma in Situ of the Breast? Journ Clin Oncol, 2006; 24(7): 1017-19.
15. Schwartz GF: The current treatment of ductal carcinoma in situ. Breast J, 2001; 7(5):308-10.
16. Boyages J, Delaney G, Taylor R: Predictors of local recurrence after treatment of ductal carcinoma in situ. Cancer, 1999; 85:616-28.
17. Silverstein MJ, Barth A, Poller DN, et al: Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer, 1995; 31A:1425-427.
18. Masetti R, Di Leone A, Franceschini G, et al: Oncoplastic techniques in the conservative surgical treatment of breast cancer: An overview. Breast J, 2006; 12(5 Suppl 2):S174-80.
19. Tunon-de-Lara C, de-Mascarel I, Mac-Grogan G, et al: Analysis of 676 cases of ductal carcinoma in situ of the breast from 1971-1995: Diagnosis and treatment- the experience of one Institute. Am J Clin Oncol, 2001; 24:531-36.
20. Fisher B, Land S, Mamounas E, et al: Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience. Semin Oncol, 2001; 28:400-18.
21. Houghton J, Grorge WD, Cuzick J, et al: Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomized controlled trial. Lancet, 2003; 362:95-102.
22. Bijker N, Meijnen P, Peterse JL, et al: Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: Ten year results of European Organization for Research and Treatment of Cancer Randomized Phase III Trial 10 853: A study by the EORTC breast cancer cooperative group and EORTC radiotherapy group. J Clin Oncol, 2006; 24:3381-387.
23. Silverstein MJ: An argument against routine use of radiotherapy for ductal carcinoma in situ. Oncol, 2003; 17:1511-533.
24. Wong JS, Kaelin CM, Troyan SL, et al: Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol, 2006; 24:1031-36.
25. Adlard JW, Bundredt NJ: Radiotherapy for ductal carcinoma in situ. Clin Oncol (R Coll Radiol), 2006; 18:179-84.
26. MacDonald HR, Silverstein MJ, Mabry H, et al: Local control in ductal carcinoma in situ treated by excision alone: Incremental benefit of larger margin. Am J Surg 2005; 190:521-25.
27. Bijker N, Peterse JL, Duchateau L, et al: Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma- in-situ: Analysis of European organization for research and treatment of cancer trial 10853. J Clin Oncol, 2001; 19:2263-271.
28. Silverstein MJ, Lagios MD, Craig PH, et al: A prognostic index for ductal carcinoma in situ of the breast. Cancer, 1996; 77:2267-274.
29. Silverstein MJ: The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003; 186:337-43.
30. Klauber-DeMore N, Tan LK, Liberman L et al: Sentinel lymph node biopsy: Is it indicated in patients with high-risk ductal carcinoma- in-situ and ductal carcinoma-in-situ with microinvasion? Ann. Surg Oncol, 2000; 7(9):636-42.
31. Veronesi P, Intra M, Vento AR, et al: Sentinel lymph node biopsy for localized ductal carcinoma in situ? Breast, 2005; 14:520-22.
32. Wilkie C, White L, Dupond E, et al: An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg, 2005; 190:563-66.
33. Goyal A, Douglass-Jones A, Monypenny I, et al: Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ: Analysis of 587 cases. Breast Cancer Res Treat, 2006; 98:311-14.
34. Lyman GH, Giuliano AE, Somerfield MR, et al: American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in earlystage breast cancer. J Clin Oncol, 2005; 23:7703-720.
35. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen in treatment of intraductal breast cancer: National surgical adjuvant breast and bowel project B-24 randomized controlled trial. Lancet, 1999; 353:1993-2000.
36. UK Coordinating Committee on Cancer Research: Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomized controlled trial. Lancet, 2003; 362:95-102.
37. Allred D, Bryant J, Land S, et al: Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: Finding from NSABP protocol B-24 [abstract]. Presented at 25th Annual San Antonio Breast Cancer Symposium; 11-14 December 2002; San Antonio, Texas; abstract 30.
38. Hird RB, Chang A, Cimmino V, et al: Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ. Cancer, 2006; 106:2113-118.